A previous clinical trial found that tamoxifen, taken for five years, reduced the risk of developing invasive breast cancer by about 50% in post-menopausal women who were at increased risk of getting the disease.
Another trial found that five years of raloxifene reduces breast cancer risk in such women by about 38%.
Under the new plans, high risk post-menopausal women could be offered the drugs for a period of five years unless they have a history of thromboembolic disease or endometrial cancer.
More top news
The actress attended the annual dinner dressed in purple and sporting a temporary tattoo in tribute to pop star Prince who died last month.
Charity says there has been a big rise in employees unfairly treating pregnant women and new mothers.
Sadiq Khan has said that his prospects of being elected London mayor could be damaged by the party's poor handling of racism accusations.